Синдром Шницлера – недостаточно диагностируемое аутовоспалительное заболевание: перспективы в настоящем и будущем

Обложка

Цитировать

Полный текст

Аннотация

Синдром Шницлера – редкое, но обычно малодиагностируемое аутовоспалительное заболевание, которое характеризуется моноклональной IgM-гаммапатией, персистирующей крапивницей, перемежающейся лихорадкой, болями в костях и артралгией или артритом. Впервые о нем сообщила д-р Лилиан Шницлер в 1972 г. Однако этот синдром остается проблемным в плане диагностики, и постановка этого диагноза обычно занимает более 5 лет. Он проявляется в виде крапивницы, артрита, органомегалии, лихорадки, лимфаденопатии, высоких значений СОЭ, лейкоцитоза и болей в костях. В его патогенезе центральными являются иммунологические нарушения и активация инфламмасом. Его типичная диагностика происходит при клинико-анамнестическом обследовании и выявлении важных признаков, в частности моноклональной гаммапатии и острой или рецидивирующей сыпи типа крапивницы. В лечении применяют синтетические препараты, в том числе анакинру, канакинумаб, рилонасепт и антагонисты IL-6 с разной степенью эффективности. Недавние исследования показали также, что растительные препараты, такие как Terminalia chebula, Emblica offcinalis, Schinus terebinthifolia, Ferula, базилик и Wedelia, могут потенциально контролировать симптомы заболевания и влиять на воспалительные пути. Перспективы медицинского применения этих растений, согласно данным, полученным in silico, предполагают дальнейшие исследования их клинического использования. При новых методах лечения, обещающих лучшие клинические исходы, болезнь Шницлера в целом является существенной терапевтической проблемой.

Об авторах

Манджу Джахар

Университет развивающихся наук и технологий Бадди

Email: manju.jakhar@baddiuniv.ac.in

магистр фармацевтики, к.м.н., доцент Фармацевтического факультет и развивающихся наук

Индия, Бадди, Химачал-Прадеш

Нидхи Рани

Университет Читкара

Автор, ответственный за переписку.
Email: nidhiprajapati8@gmail.com

магистр фармацевтики, к.м.н., доцент, Фармацевтического колледжа Читкара

Индия, Пенджаб

Рандхир Сингх

Центральный университет Пенджаба

Email: randhir.singh@cup.edu.in

магистр фармацевтики, к.м.н., доцент

Индия, Батинда, Пенджаб

Такур Гурджит Сингх

Университет Читкара

Email: nidhi.prajapatik8@gmail.com

магистр фармацевтики, д.м.н., профессор, декан Фармацевтического колледжа Читкары

Индия, Пенджаб

Список литературы

  1. Aamina M., Alhowail A., Aldubayan M., Rabbani S.I. Ameliorative Effect of Terminalia chebula on Hematological Complications Induced by Doxorubicin. Biomed. Pharmacol. J., 2020, Vol. 13, no. 3, pp. 1245-1249.
  2. Abbas S.S., Naveed S., Qamar F., Hussain S.J., Jawed S.H. Exploration & wonders of medicinal plant Asafoetida (Heeng) constituent galvanic acid as an anticancerous and antimutagenic agent. IESR J., 2015, Vol. 1, pp. 15-17.
  3. Aikawa N.E., Silva C.A., Bonfá E., Carvalho J.F. Schnitzler’s syndrome improvement after anti-TNF-alpha therapy. Joint Bone Spine, 2010, Vol. 77, no. 5, 491. doi: 10.1016/j.jbspin.2010.02.016.
  4. Allam G., Mahdi E.A., Alzahrani A.M., Abuelsaad A.S. Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines. Centr. Eur. J. Immunol., 2016, Vol. 41, no. 4, pp. 339-349.
  5. Aouba A., Pressiat C., Pricopi M., Georgin-Lavialle S., Boue F., Lievre-Castilla M.A., Marfaing-Koka A., Prevot S., Decottignies A. Complete Remission of Schnitzler Syndrome and Waldenström Macroglobulinemia under Rituximab-Cyclophosphamide-Dexamethasone. Dermatology, 2014, Vol. 230, no. 1, pp. 18-22.
  6. Asero R., Tedeschi A., Cugno M. Treatment of chronic urticaria. Immunol. Allergy Clin. North. Am., 2014, Vol. 34, no. 1, pp. 105-116.
  7. Bag A., Bhattacharyya S.K., Chattopadhyay R.R. The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac. J. Trop. Biomed., 2013, Vol. 3, no. 3, pp. 244-252.
  8. Betrains A., Staels F., Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Semin. Arthritis Rheum., 2020, Vol. 50, no. 4, pp. 636-642.
  9. Bezerra J.J. L.Usos Medicinais De Schinus terebinthifolia Raddi (Anacardiaceae) Em Diferentes Regiões Do Brasil: Uma Revisão. Ethnoscientia, 2022, Vol. 7, no. 1, 88. doi: 10.18542/ethnoscientia.v7i1.10963.
  10. Bhardwaj G., Sharma A., Gohain A., Sohal H.S., Bhatia T., Mutreja V. Extraction Techniques, Production and Economic Importance of Asafoetida Oleoresin. In: Nayik G.A., Gull A., Ganaie T.A. (eds.). Handbook of Oleoresins. CRC Press, 2022, pp. 101-128.
  11. Bhattacharyya J., Mihara K., Morimoto K., Takihara Y., Hide M. Elevated interleukin-18 secretion from monoclonal IgM+ B cells in a patient with Schnitzler syndrome. J. Am. Acad. Dermatol., 2012, Vol. 67, no. 3, pp. e118-e120.
  12. Bonnekoh H., Frischbutter S., Roll S., Maurer M., Krause K. Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. J. Allergy Clin. Immunol. Pract., 2021, Vol. 9, no. 6, pp. 2486-2489.
  13. Braud A., Lipsker D. Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management. Biomolecules, 2024, Vol. 14, no. 6, 646. doi: 10.3390/biom14060646.
  14. Bui V.-H., Vo H.T.N., Duong T.-T., Kim S.-K., Ngo D.-N. Anti-inflammatory effect of gallic acid-conjugated chitooligosaccharides in lipopolysaccharide-stimulated RAW 264.7 macrophages. VJSTE, 2024, Vol. 66, no. 1, pp. 96-103.
  15. Cao J., Ni Y., Ning X., Zhang H. Wedelolactone ameliorates synovial inflammation and cardiac complications in a murine model of collagen-induced arthritis by inhibiting NF-κB/NLRP3 inflammasome activation. Folia Histochem. Cytobiol., 2022, Vol. 60, no. 4, pp. 301-310.
  16. Cascavilla N., Bisceglia M., D’Arena G. Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. Int. J. Immunopathol. Pharmacol., 2010, Vol. 23, no. 2, pp. 633-636.
  17. Claus J., Vanderschueren S. Variable responses to tocilizumab in four patients with Schnitzler Syndrome. J. Clin. Immunol., 2019, Vol. 39, no. 4, pp. 370-372.
  18. Cuong T.T., Diem G.H., Doan T.T., Huy N.Q., Phuong N., Hung H.T. Wedelolactone from Vietnamese Eclipta prostrata (L) L. Protected Zymosan-induced shock in Mice. Iran J. Pharm. Res., 2018, Vol. 17, no. 2, pp. 653-660.
  19. de Koning H.D., Bodar E.J., van der Meer J.W., Simon A. Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin. Arthritis Rheum., 2007, Vol. 37, no. 3, pp. 137-148.
  20. de Koning HD., Schalkwijk J., van der Ven-Jongekrijg J., Stoffels M., van der Meer JW., Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann. Rheum. Dis., 2013, Vol. 72, no. 10, pp. 1634-1638.
  21. de Koning H.D., van Vlijmen-Willems I.M., Rodijk-Olthuis D., van der Meer J.W., Zeeuwen P.L., Simon A., Schalkwijk J. Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler’s syndrome. Br. J. Dermatol., 2015, Vol. 173, no. 2, pp. 448-456.
  22. de Koning H.D. Schnitzler’s syndrome: lessons from 281 cases. Clin. Transl. Allergy, 2014, Vol. 4, 41. doi: 10.1186/2045-7022-4-41.
  23. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T.J., Young M.R., Fandl J.P., Lee F., Carver S., McNay J., Bailey K., Ramakanth S., Hutabarat R., Huang T.T., Radziejewski C., Yancopoulos G.D., Stahl N. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med., 2003, Vol. 9, no. 1, pp. 47-52.
  24. Eiling E., Möller M., Kreiselmaier I., Brasch J., Schwarz T. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J. Am. Acad. Dermatol., 2007, Vol. 57, no. 2, pp. 361-364.
  25. Fagan N., Conlon N., Ridge K. DP23 Paraprotein negative Schnitzler syndrome: a new clinical entity? Br. J. Dermatol., 2023, Vol. 188, no. 4, 113.236.
  26. Garg V., Kaur B., Singh S.K., Kumar B. Terminalia chebula: Success from botany to allopathic and ayurvedic pharmacy. Asian J. Pharm. Clin. Res., 2016, Vol. 9, no. 5, 21. doi: 10.22159/ajpcr.2016.v9i5.13074.
  27. Ghasemi Z., Rezaee R., Aslani M.R., Boskabady M.H. Anti-inflammatory, anti-oxidant, and immunomodulatory activities of the genus Ferula and their constituents: A review. Iran J. Basic Med. Sci., 2021, Vol. 24, no. 12, pp. 1613-1623.
  28. Ghosh S., Kundu S. Step By Step: Urticaria & Angioedema Management. JP Medical Ltd; 2016.
  29. Han N.R., Park H.J., Moon P.D. Resveratrol downregulates granulocyte-macrophage colony-stimulating factor-induced oncostatin M Production through Blocking of PI3K/Akt/NF-κB Signal Cascade in Neutrophil-like Differentiated HL-60 Cells. Curr. Issues Mol. Biol., 2022, Vol. 44, no. 2, pp. 541-549.
  30. Henry D.P., Ranjan J., Murugan R.K., Sivanantham A., Alagumuthu M. Exploration of anti-breast cancer effects of Terminalia chebula extract on DMBA-induced mammary carcinoma in Sprague Dawley rats. Future J. Pharm. Sci., 2020, Vol. 6, 108. doi: 10.1186/s43094-020-00124-z.
  31. Hoang S.H., Dao H., Lam E.M. A network pharmacology approach to elucidate the anti-inflammatory effects of ellagic acid. J. Biomol. Struct. Dyn., 2024, Vol. 42, no. 14, pp. 7409-7420.
  32. Hoffman H.M., Wolfe F., Belomestnov P., Mellis S.J. Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr. Med. Res. Opin., 2008, Vol. 24, no. 9, pp. 2531-2543.
  33. Iranshahy M., Iranshahi M. Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin)-a review. J. Ethnopharmacol., 2011, Vol. 134, no. 1, pp. 1-10.
  34. Kacar M., Pathak S., Savic S. Hereditary systemic autoinflammatory diseases and Schnitzler’s syndrome. Rheumatology, 2019, Vol. 58, Suppl. 6, pp. vi31-vi43.
  35. Khan M.A.R., Islam M.A., Biswas K., Al-Amin M.Y., Ahammed M.S , Manik M.I.N., Islam K.M., Kader A., Alam A.K., Zaman S., Sadik G. Compounds from the Petroleum Ether Extract of Wedelia chinensis with Cytotoxic, Anticholinesterase, Antioxidant, and Antimicrobial Activities. Molecules, 2023, Vol. 28, no. 2, 793. doi: 10.3390/molecules28020793.
  36. Krause K., Feist E., Fiene M., Kallinich T., Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J. Allergy Clin. Immunol., 2012, Vol. 129, no. 3, pp. 848-850.
  37. Krause K., Tsianakas A., Wagner N., Fischer J., Weller K., Metz M., Church M.K., Maurer M. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. J. Allergy Clin. Immunol., 2017, Vol. 139, no. 4, pp. 1311-1320.
  38. Krause K., Weller K., Stefaniak R., Wittkowski H., Altrichter S., Siebenhaar F., Zuberbier T., Maurer M. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy, 2012, Vol. 67, no. 7, pp. 943-950.
  39. Krause K., Bonnekoh H., Ellrich A., Tsianakas A., Wagner N., Fischer J., Maurer M. Long-term Efficacy of Canakinumab in the Treatment of Schnitzler Syndrome. J. Allergy Clin. Immunol., 2020, Vol. 145, pp. 1681-1686.
  40. Lim W., Shumak K.H., Reis M., Perez-Ordonez B., Sauder D., Fam A., Imrie K.R. Malignant evolution of Schnitzler’s syndrome--chronic urticaria and IgM monoclonal gammopathy: report of a new case and review of the literature. Leuk. Lymphoma, 2002, Vol. 43, no. 1, pp. 181-186.
  41. Lipsker D., Veran Y., Grunenberger F., Cribier B., Heid E., Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine, 2001, Vol. 80, no. 1, pp. 37-44.
  42. Lipsker D. The Schnitzler syndrome. Orphanet J. Rare Dis., 2010, Vol. 8, no. 5, 38. doi: 10.1186/1750-1172-5-38.
  43. Liu S.J., Guo B.D., Gao Q.H., Deng Y.J, Yan B., Zeng Y., Zhao M., Ren K., Wang F., Guo J. Ursolic acid alleviates chronic prostatitis via regulating NLRP3 inflammasome-mediated Caspase-1/GSDMD pyroptosis pathway. Phytother. Res., 2024, Vol. 38, no. 1, pp. 82-97.
  44. Liu Y., Bao L., Xuan L., Song B., Lin L., Han H. Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation. Exp. Ther. Med., 2015, Vol. 10, no. 1, pp. 263-268.
  45. Martinez-Taboada V.M., Fontalba A., Blanco R., Fernández-Luna J.L. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum., 2005, Vol. 52, no. 7, pp. 2226-2227.
  46. Mazloom B.F., Edalatmanesh M.A., Hosseini S.E. Gallic acid reduces inflammatory cytokines and markers of oxidative damage in a rat model of estradiol-induced polycystic ovary. Comp. Clin. Pathol., 2019, Vol. 28, pp. 1281-1286.
  47. Mobasheri L., Khorashadizadeh M., Safarpour H., Mohammadi M., Anani Sarab G., Askari VR. Anti-Inflammatory Activity of Ferula assafoetida Oleo-Gum-Resin (Asafoetida) against TNF-α-Stimulated Human Umbilical Vein Endothelial Cells (HUVECs). Mediators Inflamm., 2022, Vol. 2022, 5171525. doi: 10.1155/2022/5171525.
  48. Murota H., Shoda Y., Ishibashi T., Sugahara H., Matsumura I., Katayama I. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J. Am. Acad. Dermatol., 2009, Vol. 61, no. 6, pp. 1070-1075.
  49. Naraki K., Rameshrad M., Hosseinzadeh H. Protective effects and therapeutic applications of ellagic acid against natural and synthetic toxicants: A review article. Iran J. Basic Med. Sci., 2022, Vol. 25, no. 12, pp. 1402-1415.
  50. Néel A., Henry B., Barbarot S., Masseau A., Perrin F., Bernier C., Kyndt X., Puechal X., Weiller PJ., Decaux O., Ninet J., Hot A., Aouba A., Astudillo L., Berthelot JM., Bonnet F., Brisseau JM., Cador B., Closs-Prophette F., Dejoie T., de Korwin JD., Dhote R., Fior R., Grosbois B., Hachulla E., Hatron PY., Jardel H., Launay D., Lorleac’h A., Pottier P., Moulis G., Serratrice J., Smail A., Hamidou M. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun. Rev., 2014, Vol. 13, no. 10, pp. 1035-1041.
  51. Nguyen-Ngo C., Salomon C., Lai A., Willcox JC., Lappas M. Anti-inflammatory effects of gallic acid in human gestational tissues in vitro. Reproduction, 2020, Vol. 160, no. 4, pp. 561-578.
  52. Palladini G., Merlini G. The elusive pathogenesis of Schnitzler syndrome. Blood. 2018, Vol. 131, no. 9, pp. 944-946.
  53. Pan H., Lin Y., Dou J., Fu Z., Yao Y., Ye S., Zhang S., Wang N., Liu A., Li X., Zhang F., Chen D. Wedelolactone facilitates Ser/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis. Cell Prolif., 2020, Vol. 53, no. 9, 12868. doi: 10.1111/cpr.12868.
  54. Pitaloka D.A.E., Cooper A.M., Artarini A.A., Damayanti S., Sukandar E.Y. Regulation of mitogen-activated protein kinase signaling pathway and proinflammatory cytokines by ursolic acid in murine macrophages infected with Mycobacterium avium. Infect. Dis. Rep., 2020, Vol. 12, Suppl. 1, 8717. doi: 10.4081/idr.2020.8717.
  55. Ramadan K.M., Eswedi H.A., El-Agnaf M.R. Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br. J. Dermatol., 2007, Vol. 156, no. 5, pp. 1072-1074.
  56. Rani N., Singh R., Kumar P. In silico studies of plant-derived bioactive compounds of Wedelia Species. Anti-Infective Agents, 2022, Vol. 20, no. 5, pp. 56-62.
  57. Rao S.K., Sharma A., Jain D. A review medicinal and traditional uses on Tulsi plant (Ocimum sanctum L.). World J. Biol. Pharm. Health Sci., 2023, Vol. 13, no. 1, pp. 450-456.
  58. Rigante D. The Broad-Ranging Panorama of Systemic Autoinflammatory Disorders with Specific Focus on Acute Painful Symptoms and Hematologic Manifestations in Children. Mediterr. J. Hematol. Infect. Dis., 2018 , Vol. 10, no. 1, e2018067. doi: 10.4084/mjhid.2018.067.
  59. Rosas E.C., Correa L.B., das Graças Henriques M. Chapter 28 – Antiinflammatory Properties of Schinus terebinthifolius and Its Use in Arthritic Conditions. In: Watson R.R., Preedy V.R. (eds.). Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases. 2nd ed. Academic Press, 2019, pp. 489-505.
  60. Rowczenio D.M., Pathak S., Arostegui J.I., Mensa-Vilaro A., Omoyinmi E., Brogan P., Lipsker D., Scambler T., Owen R., Trojer H., Baginska A., Gillmore J.D., Wechalekar A.D., Lane T., Williams R., Youngstein T., Hawkins P.N., Savic S., Lachmann H.J. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood, 2018, Vol. 131, no. 9, pp. 974-981.
  61. Sahiba N., Sethiya A., Agarwal D.K., Agarwal S. An Overview on Immunity Booster Foods in Coronavirus Disease (COVID-19). Comb. Chem. High Throughput Screen. 2023, Vol. 26, no. 7, pp. 1251-1284.
  62. Sahoo D.D., Tabassum Y., Sharma D. Multiple health benefits of tulsi plants. J. Med. Plants Stud., 2022, Vol. 10, no. 5, pp. 95-102.
  63. Sharma K., Kumar S., Prakash R., Khanka S., Mishra T., Rathur R., Biswas A., Verma S.K., Bhatta R.S., Narender T., Singh D. Chebulinic acid alleviates LPS-induced inflammatory bone loss by targeting the crosstalk between reactive oxygen species/NFκB signaling in osteoblast cells. Free Radic. Biol. Med.. 2023, Vol. 194, pp. 99-113.
  64. Sokumbi O., Drage LA., Peters M.S. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972-2011). J. Am. Acad. Dermatol., 2012, Vol. 67, no. 6, pp. 1289-1295.
  65. Singh S., Shukla A., Semwal BC. Semwal, Phytochemical and Pharmacological Potential of Ferula asafetida “Hing”. Curr. Bioact. Compd., Vol. 2024, Vol. 20, no. 3, e260623218247. doi: 10.2174/1573407219666230626111830.
  66. Sood R. Asafoetida (Ferula asafoetida): A high-value crop suitable for the cold desert of Himachal Pradesh, India. J. Appl. Nat. Sci., 2020, Vol. 12, no. 4, pp. 607-617.
  67. Srivatsav V., Milne A., Hofeld K., Abbas M. Case report on the rare diagnosis of Schnitzler’s Syndrome. Can. J. Gen. Intern. Med., 2022, Vol. 17, no. 4, pp. 1-5.
  68. Sun X.Q., Zhang Z. AB1857 A First Case Report Of Schnitzler Syndrome Presenting With Acropachy And Literature Review. Ann. Rheum. Dis., 2023, Vol. 2156, pp. 2156-2157.
  69. Takimoto-Ito R., Kambe N., Kogame T., Otsuka A., Nomura T., Izawa K., Tabuchi Y., Yoshifuji H., Takeuchi Y., Kabashima K. Refractory serum immunoglobulin M elevation during anti-interleukin (IL)-1- or IL- 6-targeted treatment in four patients with Schnitzler syndrome. J. Dermatol., 2021, Vol. 48, no. 11, pp. 1789-1792.
  70. Thakur S., Choudhary S., Walia B., Chaudhary G. Tulsi – a review based upon its ayurvedic and modern therapeutic uses. Int. J. Res. Rev., 2021, Vol. 8, no. 5, pp. 263-272.
  71. Thonhofer R., Uitz E., Graninger W. Schnitzler’s syndrome – exacerbation after anti-TNF treatment. Rheumatology, 2007, Vol. 46, no. 6, pp. 1041-1042.
  72. Tinazzi E., Puccetti A., Patuzzo G., Sorleto M., Barbieri A., Lunardi C. Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature. Autoimmun. Rev., 2011, Vol. 10, no. 7, pp. 404-409.
  73. Tsai Y.-T., To K.-Y. Plant Regeneration from Leaf Explants of the Medicinal Herb Wedelia chinensis. Horticulturae 2021, Vol. 7, 407. doi: 10.3390/ horticulturae7100407.
  74. Tsiogkas SG., Apostolopoulou K., Mavropoulos A., Grammatikopoulou M.G., Dardiotis E., Zafiriou E., Bogdanos D.P. Gallic acid diminishes pro-inflammatory interferon-γ- and interleukin-17-producing sub-populations in vitro in patients with psoriasis. Immunol. Res., 2023, Vol. 71, no. 3, pp. 475-487.
  75. Vasconcelos P.G., Alves É.P., Maia C.M., Brito A.C., Silva D.R., Freires I.A., Cavalcanti Y.W., Rehder V.L., Ruiz A.L., Duarte M.C., Rosalen P.L. Biological properties of Schinus terebinthifolia Raddi essential oil. Braz. J. Pharm. Sci., 2022, Vol. 58, e20417. doi: 10.1590/s2175-97902021000X2e20417.
  76. Villarreal RS., VandenBoom T., Gonzalez-Gonzalez FJ., Carter R.G., Peters N.T., Peters A.T., Chiarella S.E. Schnitzler syndrome with IgG gammopathy and elevated IL-1β and IL-17 in skin biopsy. Ann. Allergy Asthma Immunol., 2018, Vol. 120, no. 1, pp. 99-101.
  77. Wesselmann A.S., Künstner A., Fähnrich A., Rose C., Lamprecht P., Busch H., Ludwig R.J., Recke A. Case report: Schnitzler-like syndrome without monoclonal gammopathy. Front. Immunol., 2023, Vol. 14, 1166620. doi: 10.3389/fimmu.2023.1166620.
  78. Westhoff T.H., Zidek W., Uharek L., Steinhoff-Georgieva J., van der Giet M. Impairment of renal function in Schnitzler’s syndrome. J. Nephrol., 2006, Vol. 19, no. 5, pp. 660-663.
  79. Yan R., Cao W., Liu X., Li F., Shen M. A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. Clin. Rheumatol., 2020, Vol. 39, no. 12, pp. 3847-3852.
  80. Zamudio-Cuevas Y., Andonegui-Elguera M.A., Aparicio-Juárez A., Aguillón-Solís E., Martínez-Flores K., Ruvalcaba-Paredes E., Velasquillo-Martínez C., Ibarra C., Martínez-López V., Gutiérrez M., García-Arrazola R., Hernández-Valencia C.G., Romero-Montero A., Hernández-Valdepeña M.A., Gimeno M., Sánchez-Sánchez R. The enzymatic poly(gallic acid) reduces pro-inflammatory cytokines in vitro, a potential application in inflammatory diseases. Inflammation, 2021, Vol. 44, no. 1, pp. 174-185.
  81. Zhang J., Zhang M., Huo X.K., Ning J., Yu Z.L., Morisseau C., Sun C.P., Hammock B.D., Ma X.C. Macrophage Inactivation by Small Molecule Wedelolactone via Targeting sEH for the Treatment of LPS-Induced Acute Lung Injury. ACS Cent. Sci., 2023, Vol. 9, no. 3, pp. 440-456.
  82. Zhang C. Therapeutic mechanisms of ellagic acid for inflammation and related conditions. International Conference on Modern Medicine and Global Health, 2023, Vol. 7, no. 12789, pp. 703-708.
  83. Zhao M., Wu F., Tang Z., Yang X., Liu Y., Wang F., Chen B. Anti-inflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis. Front. Pharmacol., 2023, Vol. 14, 1256946. doi: 10.3389/fphar.2023.1256946.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Джахар М., Рани Н., Сингх Р., Сингх Т., 2026

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).